These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 24970481)

  • 1. Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer.
    Hsu YH; Yao J; Chan LC; Wu TJ; Hsu JL; Fang YF; Wei Y; Wu Y; Huang WC; Liu CL; Chang YC; Wang MY; Li CW; Shen J; Chen MK; Sahin AA; Sood A; Mills GB; Yu D; Hortobagyi GN; Hung MC
    Cancer Res; 2014 Sep; 74(17):4822-35. PubMed ID: 24970481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer.
    Weng TH; Yao MY; Xu XM; Hu CY; Yao SH; Liu YZ; Wu ZG; Tang TM; Fu PF; Wang MH; Yao HP
    Cancer Res Treat; 2020 Jul; 52(3):973-986. PubMed ID: 32324988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
    Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
    Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
    Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
    Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A.
    Breen L; Gaule PB; Canonici A; Walsh N; Collins DM; Cremona M; Hennessy BT; Duffy MJ; Crown J; Donovan NO; Eustace AJ
    Invest New Drugs; 2020 Oct; 38(5):1365-1372. PubMed ID: 32318883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
    Lee J; Lim B; Pearson T; Choi K; Fuson JA; Bartholomeusz C; Paradiso LJ; Myers T; Tripathy D; Ueno NT
    Breast Cancer Res Treat; 2019 Jun; 175(2):339-351. PubMed ID: 30826934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
    Zhang H; Cohen AL; Krishnakumar S; Wapnir IL; Veeriah S; Deng G; Coram MA; Piskun CM; Longacre TA; Herrler M; Frimannsson DO; Telli ML; Dirbas FM; Matin AC; Dairkee SH; Larijani B; Glinsky GV; Bild AH; Jeffrey SS
    Breast Cancer Res; 2014 Apr; 16(2):R36. PubMed ID: 24708766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
    Shen Y; Zhang W; Liu J; He J; Cao R; Chen X; Peng X; Xu H; Zhao Q; Zhong J; Ding W; Lei X; Jiang Y; Zu X
    Int J Cancer; 2019 Feb; 144(3):651-664. PubMed ID: 30289981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERN1 and ALPK1 inhibit differentiation of bi-potential tumor-initiating cells in human breast cancer.
    Strietz J; Stepputtis SS; Preca BT; Vannier C; Kim MM; Castro DJ; Au Q; Boerries M; Busch H; Aza-Blanc P; Heynen-Genel S; Bronsert P; Kuster B; Stickeler E; Brabletz T; Oshima RG; Maurer J
    Oncotarget; 2016 Dec; 7(50):83278-83293. PubMed ID: 27829216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-200b targets protein kinase Cα and suppresses triple-negative breast cancer metastasis.
    Humphries B; Wang Z; Oom AL; Fisher T; Tan D; Cui Y; Jiang Y; Yang C
    Carcinogenesis; 2014 Oct; 35(10):2254-63. PubMed ID: 24925028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
    Martin JL; Julovi SM; Lin MZ; de Silva HC; Boyle FM; Baxter RC
    Breast Cancer Res; 2017 Aug; 19(1):90. PubMed ID: 28778177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
    Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
    Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p38γ MAPK Is a Therapeutic Target for Triple-Negative Breast Cancer by Stimulation of Cancer Stem-Like Cell Expansion.
    Qi X; Yin N; Ma S; Lepp A; Tang J; Jing W; Johnson B; Dwinell MB; Chitambar CR; Chen G
    Stem Cells; 2015 Sep; 33(9):2738-47. PubMed ID: 26077647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
    Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
    Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein kinase C inhibitor chelerythrine selectively inhibits proliferation of triple-negative breast cancer cells.
    Lin W; Huang J; Yuan Z; Feng S; Xie Y; Ma W
    Sci Rep; 2017 May; 7(1):2022. PubMed ID: 28515445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
    He J; McLaughlin RP; van der Noord V; Foekens JA; Martens JWM; van Westen G; Zhang Y; van de Water B
    Breast Cancer Res Treat; 2019 Nov; 178(2):263-274. PubMed ID: 31388935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strictinin, a novel ROR1-inhibitor, represses triple negative breast cancer survival and migration via modulation of PI3K/AKT/GSK3ß activity.
    Fultang N; Illendula A; Chen B; Wu C; Jonnalagadda S; Baird N; Klase Z; Peethambaran B
    PLoS One; 2019; 14(5):e0217789. PubMed ID: 31150511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rutin as A Novel c-Met Inhibitory Lead for The Control of Triple Negative Breast Malignancies.
    Elsayed HE; Ebrahim HY; Mohyeldin MM; Siddique AB; Kamal AM; Haggag EG; El Sayed KA
    Nutr Cancer; 2017; 69(8):1256-1271. PubMed ID: 29083228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer.
    Li B; Ni Chonghaile T; Fan Y; Madden SF; Klinger R; O'Connor AE; Walsh L; O'Hurley G; Mallya Udupi G; Joseph J; Tarrant F; Conroy E; Gaber A; Chin SF; Bardwell HA; Provenzano E; Crown J; Dubois T; Linn S; Jirstrom K; Caldas C; O'Connor DP; Gallagher WM
    Cancer Res; 2017 Jul; 77(14):3834-3845. PubMed ID: 28455421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Targeting of Stromal-Tumor HGF-MET Signaling in an Organotypic Triple-Negative Breast Tumor Model.
    Singh S; Lamichhane A; Rafsanjani Nejad P; Heiss J; Baumann H; Gudneppanavar R; Leipzig ND; Konopka M; Luker GD; Tavana H
    Mol Cancer Res; 2022 Jul; 20(7):1166-1177. PubMed ID: 35348758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.